Evidence map›Paper›PMID 25829142›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

Selective Estrogen Receptor Modulation Increases Hippocampal Activity during Probabilistic Association Learning in Schizophrenia.

Jochen Kindler, Cynthia Shannon Weickert, Ashley J Skilleter, Stanley V Catts, Rhoshel Lenroot, Thomas W Weickert

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Gaps or links between hormonal therapy and schizophrenia? (Review).Experimental and therapeutic medicine · 2020
    Review
  9. Review
  10. The Role of Estrogen in Brain and Cognitive Aging.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019
    Review
  11. Article
  12. Review
  13. Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders.The Journal of pharmacology and experimental therapeutics · 2017
    Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Hormone modulation improves cognition in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jochen Kindler1] School of Psychiatry, University of New South Wales, Randwick, NSW, Australia [2] Neuroscience Research Australia, Randwick, NSW, Australia [3] Department of Psychiatric Neurophysiology, University of Bern, Bern, Switzerland.
Cynthia Shannon Weickert1] School of Psychiatry, University of New South Wales, Randwick, NSW, Australia [2] Neuroscience Research Australia, Randwick, NSW, Australia [3] Schizophrenia Research Institute, Darlinghurst, NSW, Australia.
Ashley J Skilleter1] School of Psychiatry, University of New South Wales, Randwick, NSW, Australia [2] Neuroscience Research Australia, Randwick, NSW, Australia [3] Schizophrenia Research Institute, Darlinghurst, NSW, Australia.
Stanley V CattsSchool of Medical Science, University of Queensland, Brisbane, QLD, Australia.
Rhoshel Lenroot1] School of Psychiatry, University of New South Wales, Randwick, NSW, Australia [2] Neuroscience Research Australia, Randwick, NSW, Australia [3] Schizophrenia Research Institute, Darlinghurst, NSW, Australia.
Thomas W Weickert1] School of Psychiatry, University of New South Wales, Randwick, NSW, Australia [2] Neuroscience Research Australia, Randwick, NSW, Australia [3] Schizophrenia Research Institute, Darlinghurst, NSW, Australia.ORCID 000000026408718X
UNSW Sydney · AUNeuroscience Research Australia · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with schizophrenia show probabilistic association learning impairment in conjunction with abnormal neural activity. The selective estrogen receptor modulator (SERM) raloxifene preserves neural activity during memory in healthy older men and improves memory in schizophrenia. Here, we tested the extent to which raloxifene modifies neural activity during learning in schizophrenia. Nineteen people with schizophrenia participated in a twelve-week randomized, double-blind, placebo-controlled, cross-over adjunctive treatment trial of the SERM raloxifene administered orally at 120 mg daily to assess brain activity during probabilistic association learning using functional magnetic resonance imaging (fMRI). Raloxifene improved probabilistic association learning and significantly increased fMRI BOLD activity in the hippocampus and parahippocampal gyrus relative to placebo. A separate region of interest confirmatory analysis in 21 patients vs 36 healthy controls showed a positive association between parahippocampal neural activity and learning in patients, but no such relationship in the parahippocampal gyrus of healthy controls. Thus, selective estrogen receptor modulation by raloxifene concurrently increases activity in the parahippocampal gyrus and improves probabilistic association learning in schizophrenia. These results support a role for estrogen receptor modulation of mesial temporal lobe neural activity in the remediation of learning disabilities in both men and women with schizophrenia.

Indexed as

Learning DisabilitiesAssociation LearningCross-Over StudiesDouble-Blind MethodFemaleHippocampusHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleOxygenRaloxifene HydrochlorideReceptors, EstrogenSchizophreniaSelective Estrogen Receptor ModulatorsOxygenRaloxifene HydrochlorideReceptors, EstrogenSelective Estrogen Receptor Modulators

Identifiers

PMID25829142
PMCPMC4538353
OpenAlexW2050611389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.